Biocon Limited, India's second largest bio-technology firm, has announced the launch of Basalog, a human insulin analogue, which attempts to relieve diabetic patients of frequent insulin shots in a day.
According to Biocon, this new product is effective for 24 hours.
The company which is primarily focussing on finding diabetes and cancer care drugs, is parallely working on oral insulin which will further alleviate the trauma of diabetic patients having to take frequent injections of insulin substitute.
The new offering while being effective for 24 hours will also help in avoiding low blood sugar, and better glucose control in the body.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app